Latest 10-Q quarterly reports

Abeona Therapeutics Inc. reported its second quarter 2026 financial results, highlighting $11.4 million in product revenue from ZEVASKYN, while also disclosing ongoing operational losses and manufacturing hurdles.

Cocrystal Pharma, Inc. reported its second quarter 2026 financial results, highlighting ongoing research and development efforts but also substantial net losses and a critical need for future financing.

Pelthos Therapeutics Inc. filed its Q2 2026 Form 10-Q, detailing a substantial net loss, a material weakness in financial reporting, and updates on its product portfolio and financing.

Avai Bio, Inc. (AVAI) filed its Q2 2026 10-Q, revealing no revenue, increased net losses, and significant concerns regarding its ability to continue as a going concern.

Spire Global's Q2 2026 results show a 6% revenue decline year-over-year, driven by the sale of its maritime business, alongside increased cost of revenue and operating expenses, impacting gross margin.

McGraw Hill's Q2 2026 results show a 2.6% revenue increase to $549.9 million and a significant jump in net income to $57.9 million, driven by Higher Education and K-12 segments.

Zenas BioPharma reported increased operating expenses and net losses in its Q2 2026 10-Q filing, alongside progress in its late-stage clinical trials for immunology and inflammation therapies.

BK Technologies Corporation announced its second quarter 2026 financial results, showcasing a 10.6% increase in net sales and improved gross profit margins, driven by strong performance in its BKR series radios.

Venu Holding Corporation reported a wider net loss for Q2 2026, driven by increased operating costs and significant investments in new venue development, although total revenues saw a modest increase.

Charlotte's Web Holdings, Inc. reported a 15.2% decrease in revenue for the three months ended June 30, 2026, alongside a net loss of $4.1 million.

Pelthos Therapeutics Inc. has filed an amendment to its Q1 2026 report to restate financial statements due to errors in convertible debt valuation, revealing a material weakness in internal controls.

SBC Medical Group Holdings Incorporated announced a significant increase in revenue and net income for the second quarter of 2026, driven by strong performance in management services and the inclusion of the Waqoo segment.

Cellectar Biosciences reported increased R&D spending and positive clinical trial data for iopofosine I 131, but faces substantial doubt regarding its ability to continue as a going concern.

Aveanna Healthcare Holdings Inc. announced a significant increase in revenue and net income for the second quarter ended July 4, 2026, driven by strong performance across its segments and strategic acquisitions.

Aebi Schmidt Holding AG's Q2 2026 results show a substantial revenue surge and improved profitability, largely due to the integration of The Shyft Group, despite ongoing internal control remediation.

Rockwell Medical's Q2 2026 Form 10-Q filing reveals a slight increase in net sales and improved gross profit, but continued net losses, with management highlighting efforts towards sustainable profitability and potential capital raises.

Hepion Pharmaceuticals' Q2 2026 report highlights significant operating losses, a substantial accumulated deficit, and material weaknesses in internal controls, raising concerns about its ability to continue as a going concern despite recent financing.

The Elmet Group Co. has adopted an executive compensation clawback policy, effective April 17, 2026, to comply with SEC Rule 10D-1 and Nasdaq Listing Rule 5608.

Lithium Americas Corp. reports substantial progress on its Thacker Pass project, bolstered by significant funding from the DOE and GM, with construction advancing towards its late 2027 mechanical completion target.

Fervo Energy reports significant progress following its May 2026 IPO, with substantial capital expenditures for geothermal projects, while navigating operational and financial risks.

AleAnna, Inc. announced a substantial increase in revenue and a move to profitability in its Q2 2026 report, driven by its conventional natural gas segment.

Idaho Strategic Resources Inc. announced a significant increase in revenue and net income for the second quarter of 2026, driven by higher gold prices and operational improvements.

Transuite.Org Inc. filed its Q2 2026 10-Q, detailing revenue growth from e-bike charging and online education, but also reporting increased net losses and a substantial accumulated deficit.

enCore Energy Corp. reported a net loss of $41.4 million for Q2 2026, with revenues increasing to $15.7 million, but facing higher costs and operational delays.

YETI Holdings, Inc. announced robust Q2 2026 results with a 9% increase in net sales and a significant expansion in gross margin, largely attributed to IEEPA tariff refunds.

Gyrodyne, LLC's Q2 2026 Form 10-Q details its ongoing liquidation strategy focused on maximizing value for its Cortlandt Manor and Flowerfield properties, with an estimated completion date of December 31, 2028.

X-Energy, Inc. (X-energy) filed its Form 10-Q for the quarter ended June 30, 2026, detailing significant revenue increases driven by its Advanced Reactor Demonstration Program (ARDP) work, alongside ongoing development of its Xe-100 reactor and TRISO-X fuel technology.

Jones Soda Co. announced its Q2 2026 financial results, showing a significant 108% increase in revenue to $10.2 million, driven by strong performance in Fallout branded products, though the company reported a net loss of $0.7 million.

Quality Industrial Corp. (QIND) reported a decrease in revenue for the three and six months ended June 30, 2026, alongside persistent financial challenges including convertible note defaults and significant acquisition-related obligations.

Launchpad Cadenza Acquisition Corp I reports on its financial condition and operational activities for the quarter ended June 30, 2026, highlighting interest income and ongoing efforts to identify a business combination.